PDCD1 and neoplasm: Blocking the PD‐1 pathway, which allows tumors to evade the immune system; as a humanized monoclonal antibody, it binds to PD‐1 receptors on immune cells, preventing tumor cells from interacting with their PD‐L1 ligands.